Homology Medicines Revenue and Competitors
Estimated Revenue & Valuation
- Homology Medicines's estimated annual revenue is currently $3.7M per year.
- Homology Medicines's estimated revenue per employee is $32,566
- Homology Medicines's total funding is $187M.
- Homology Medicines's current valuation is $210.9M. (January 2022)
Employee Data
- Homology Medicines has 113 Employees.
- Homology Medicines grew their employee count by -25% last year.
Homology Medicines Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $7M | 45 | 73% | N/A | N/A |
#10 | $5.4M | 35 | 3% | N/A | N/A |
What Is Homology Medicines?
Homology Medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.
keywords:N/A
$187M
Total Funding
113
Number of Employees
$3.7M
Revenue (est)
-25%
Employee Growth %
$210.9M
Valuation
N/A
Accelerator
Homology Medicines News
2022-04-17 - Homology Medicines Announces Promotion of Albert ...
BEDFORD, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today...
2022-04-17 - Homology Medicines Announces Promotion of Albert ...
BEDFORD, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today...
Other Companies in Bedford
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $16.4M | 113 | -14% | N/A |
#2 | $18M | 116 | -5% | N/A |
#3 | $29.1M | 116 | -6% | N/A |
#4 | $19.1M | 116 | 0% | $235.1M |
#5 | $17.7M | 118 | 7% | N/A |